These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38284925)

  • 1. Feasibility of a telehealth-based contingency management intervention for alcohol use disorders using the phosphatidylethanol (PEth) 16:0/18:1 alcohol biomarker: a pilot randomized trial.
    Jett JD; Beck R; Tyutyunnyk D; Sanchez J; Weeks DL; Javors MA; Hill-Kapturczak N; Lopez-Cruzan M; Kriegel L; Ginsburg BC; Cabassa L; McDonell MG
    Am J Drug Alcohol Abuse; 2024 Mar; 50(2):162-172. PubMed ID: 38284925
    [No Abstract]   [Full Text] [Related]  

  • 2. Pilot investigation of a phosphatidylethanol-based contingency management intervention targeting alcohol use.
    McDonell MG; Skalisky J; Leickly E; Orr MF; McPherson S; Roll J; Hill-Kapturczak N; Javors M
    Psychol Addict Behav; 2017 Aug; 31(5):608-613. PubMed ID: 28714726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the quantification of phosphatidylethanol 16:0/18:1 concentrations in TASSO-M20 devices.
    Jett JD; Beck R; Tyutyunnyk D; Sanchez J; Lopez-Cruzan M; Ginsburg BC; McPherson SM; Javors MA; McDonell MG; Hill-Kapturczak N
    Alcohol Clin Exp Res (Hoboken); 2023 Apr; 47(4):748-755. PubMed ID: 36811188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed-methods trial of a phosphatidylethanol-based contingency management intervention to initiate and maintain alcohol abstinence in formerly homeless adults with alcohol use disorders.
    Fraser ER; Hill-Kapturczak N; Jett J; Beck R; Oluwoye O; Kriegel LS; Alcover KC; McPherson S; Cabassa LJ; Javors M; McDonell MG
    Contemp Clin Trials Commun; 2021 Jun; 22():100757. PubMed ID: 33763620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations Between the Phosphatidylethanol Alcohol Biomarker and Self-Reported Alcohol Use in a Sample of HIV-Infected Outpatient Drinkers in Western Kenya.
    Papas RK; Gakinya BN; Mwaniki MM; Keter AK; Lee H; Loxley MP; Klein DA; Sidle JE; Martino S; Baliddawa JB; Schlaudt KL; Maisto SA
    Alcohol Clin Exp Res; 2016 Aug; 40(8):1779-87. PubMed ID: 27426424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validating Self-Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV.
    Eyawo O; Deng Y; Dziura J; Justice AC; McGinnis K; Tate JP; Rodriguez-Barradas MC; Hansen NB; Maisto SA; Marconi VC; O'Connor PG; Bryant K; Fiellin DA; Edelman EJ
    Alcohol Clin Exp Res; 2020 Oct; 44(10):2053-2063. PubMed ID: 33460225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylethanol (PEth) detected in blood for 3 to 12 days after single consumption of alcohol-a drinking study with 16 volunteers.
    Schröck A; Thierauf-Emberger A; Schürch S; Weinmann W
    Int J Legal Med; 2017 Jan; 131(1):153-160. PubMed ID: 27596747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of phosphatidylethanol (PEth) in whole blood in comparison to ethyl glucuronide in hair (hEtG) in driving aptitude assessment (DAA).
    Schröck A; Pfäffli M; König S; Weinmann W
    Int J Legal Med; 2016 Nov; 130(6):1527-1533. PubMed ID: 27255372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease.
    Stewart SH; Koch DG; Willner IR; Anton RF; Reuben A
    Alcohol Clin Exp Res; 2014 Jun; 38(6):1706-11. PubMed ID: 24848614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The roles of phosphatidylethanol, ethyl glucuronide, and ethyl sulfate in identifying alcohol consumption among participants in professionals health programs.
    Reisfield GM; Teitelbaum SA; Opie SO; Jones J; Morrison DG; Lewis B
    Drug Test Anal; 2020 Aug; 12(8):1102-1108. PubMed ID: 32309913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of Phosphatidylethanol Biomarker to Self-Reported Alcohol Drinking Patterns in Older and Middle-Age Adults.
    Cherrier MM; Shireman LM; Wicklander K; Yeung W; Kooner P; Saxon AJ; Simpson T; Terman G; Shen D
    Alcohol Clin Exp Res; 2020 Dec; 44(12):2449-2456. PubMed ID: 33038267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylethanol in Comparison to Self-Reported Alcohol Consumption Among HIV-Infected Women in a Randomized Controlled Trial of Naltrexone for Reducing Hazardous Drinking.
    Wang Y; Chen X; Hahn JA; Brumback B; Zhou Z; Miguez MJ; Cook RL
    Alcohol Clin Exp Res; 2018 Jan; 42(1):128-134. PubMed ID: 29080351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary Analysis of a Randomized Clinical Trial of Naltrexone Among Women Living With HIV: Correlations Between Reductions in Self-Reported Alcohol Use and Changes in Phosphatidylethanol.
    Richards VL; Sajdeya R; Villalba K; Wang Y; Bryant V; Brumback B; Bryant K; Hahn JA; Cook RL
    Alcohol Clin Exp Res; 2021 Jan; 45(1):174-180. PubMed ID: 33190242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylethanol is superior to carbohydrate-deficient transferrin and γ-glutamyltransferase as an alcohol marker and is a reliable estimate of alcohol consumption level.
    Walther L; de Bejczy A; Löf E; Hansson T; Andersson A; Guterstam J; Hammarberg A; Asanovska G; Franck J; Söderpalm B; Isaksson A
    Alcohol Clin Exp Res; 2015 Nov; 39(11):2200-8. PubMed ID: 26503066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination Characteristics of the Alcohol Biomarker Phosphatidylethanol (PEth) in Blood during Alcohol Detoxification.
    Helander A; Böttcher M; Dahmen N; Beck O
    Alcohol Alcohol; 2019 May; 54(3):251-257. PubMed ID: 30968936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of direct alcohol markers in alcohol use disorder patients during withdrawal treatment and successive rehabilitation.
    Luginbühl M; Weinmann W; Butzke I; Pfeifer P
    Drug Test Anal; 2019 Jun; 11(6):859-869. PubMed ID: 30618164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a novel method for the analysis of alcohol biomarkers: Ethyl glucuronide, ethyl sulfate and phosphatidylethanol.
    Nguyen VL; Paull P; Haber PS; Chitty K; Seth D
    Alcohol; 2018 Mar; 67():7-13. PubMed ID: 29304397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An automated sample preparation approach for routine liquid chromatography tandem-mass spectrometry measurement of the alcohol biomarkers phosphatidylethanol 16:0/18:1, 16:0/16:0 and 18:1/18:1.
    Casati S; Ravelli A; Angeli I; Durello R; Minoli M; Orioli M
    J Chromatogr A; 2019 Mar; 1589():1-9. PubMed ID: 30598290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing phosphatidylethanol (PEth) levels reflecting different drinking habits in comparison to the alcohol use disorders identification test - C (AUDIT-C).
    Schröck A; Wurst FM; Thon N; Weinmann W
    Drug Alcohol Depend; 2017 Sep; 178():80-86. PubMed ID: 28645063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Set-up of a population-based model to verify alcohol abstinence via monitoring of the direct alcohol marker phosphatidylethanol 16:0/18:1.
    Van Uytfanghe K; Heughebaert L; Abatih E; Stove CP
    Addiction; 2022 Jul; 117(7):2108-2118. PubMed ID: 35072319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.